02.12.2021 - WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) - Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of ... Seite 1